N/A N=60 The Prostate Immobilization Device Study
Adenocarcinoma of the Prostate
Primary: Deviation of the Prostate Rectal Interface From Its Position at Time of Simulation. — .319; .095 CENTIMETERS
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=95 Predicting Location and Extent of Prostate Cancer Using Micro-Ultrasound Imaging
Prostate Cancer
Primary: Micro-Ultrasound Detection of High Grade Prostate Cancer (Gleason Score ≥7) vs. Surgical Pathology — 38; 50 participants
Phase 3 N=62 PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
Healthy
Primary: Prostate Tissue DHT Concentrations After Treatment — 4.05; 4.26; 2.99; 3.88 ng/g
Phase 2 N=92 Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Change in International Prostate Symptom Scale (IPSS) of Lower Urinary Tract Symptoms From Baseline to 3 Months (Total Score at 3 Months Minus Total Score at Baseline)…
N/A N=9 Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Prostatic Hyperplasia, Benign · Enlarged Prostate With Lower Urinary Tract Symptoms
Primary: Number of Participants With Adverse Events — 3 Participants
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 2 N=33 Green Tea Extract and Prostate Cancer
Prostate Cancer
Primary: Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer — 0.86 ng/mL — p==0.027
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 2 N=30 Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
PSA Level Less Than or Equal to Fifteen · PSA Level Less Than Ten · Stage I Prostate Cancer AJCC v7
Primary: Change in Plasma IGF-1 From Baseline to Post-Treatment — 19.12; 8.54 ng/mL — p=0.190
Phase 2 N=27 Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Prostate Cancer · Prostatic Neoplasms · Neoplasms, Prostate
Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…
N/A N=21 Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia
Primary: Number of Adverse Events Reported — 7 adverse events
N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Phase 3 N=32 PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue
Healthy
Primary: Prostate-specific Antigen (PSA) — 0.8; 0.9; 0.7; 0.4 ng/mL
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
Phase 2 N=24 PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort) — 1; 1; 1; 1 Participants
N/A N=45 Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH)
Primary: The Primary Objective is to Evaluate the Safety of Prostate Artery Embolization (PAE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign…
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
N/A N=45 Study of Median Lobe Prostatic UroLift Procedure
Benign Prostatic Hyperplasia (BPH)
Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change
N/A N=25 MRI- Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer
MRI Guided Transurethral Ultrasound Ablation · Localized Prostate Cancer · Ablation Therapy
Primary: Absence of Clinically Significant Cancer (CSC) on Control Biopsy at 1-year Follow-up. — 8 Participants
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 3 N=420 Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Benign Prostatic Hypertrophy
Primary: International Prostate Symptom Score (IPSS) — -6.2; -5.1; -5.7 Units on a scale — p=0.371
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
N/A N=28 Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres
Benign Prostatic Hyperplasia (BPH)
Primary: Number of Reported Treatment-related Adverse Events (AE) as Assessed by NCI CTCAE Grading Scale . — 6; 10; 0; 0 events — p=0.05
Phase 2 N=51 The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Prostate Cancer
Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05
N/A N=24 Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate Cancer · Magnetic Resonance Imaging · Target Lesion
Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants
N/A N=6 Focal Prostate Radio-Frequency Ablation
Prostate Cancer
Primary: Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA) — 3; 2; 1 Participants
N/A N=130 Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
Prostatic Neoplasms
Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants
N/A N=35 High-Dose Stereotactic Radiation for Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants
N/A N=44 Effect of Weight Loss on Prostate Cancer Pathology
Obesity · Prostate Cancer
Primary: Apoptotic Index of the Highest Gleason Grade Malignant Epithelium in the Radical Prostatectomy Specimen Obtained After 8-weeks of the Dietary Intervention — 6.9; 5.0…